A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera® / Ristova® (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin lymphoma - Nil

Trial Profile

A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD, Russia) efficacy and safety in comparison with MabThera® / Ristova® (F. Hoffmann-La Roche Ltd., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin lymphoma - Nil

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Biocad
  • Most Recent Events

    • 18 Jul 2017 Status changed from recruiting to completed.
    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top